Beilstein J. Nanotechnol.2023,14, 240–261, doi:10.3762/bjnano.14.23
therapy, leading to the rapid exhaustion of standard molecularly targeted therapeutic options against mutant variants. Attacking multiple molecular targets within one or several signaling pathways by co-delivery of multiple agents is a viable strategy for overcomingandpreventingresistance to EGFR TKIs
intracellular internalization, and bring advantages over conventional nanocarriers.
Keywords: co-delivery nanoparticles; combinatorial therapy; EGFR TKI resistance; non-small cell lung cancer (NSCLC); overcomingandpreventingresistance; Introduction
Among the malignant diseases, lung cancer takes the lead
PDF
Figure 1:
Examples of combinatorial therapy for (left) EGFR-dependent and (right) EGFR-independent TKI resist...